US gov­ern­men­t's court bat­tle be­gins over Gilead HIV drug patents

Ju­ry se­lec­tion be­gins to­day in a Delaware fed­er­al court for the law­suit that kicked off in 2019 when the fed­er­al gov­ern­ment sued Gilead, al­leg­ing that the sale of its HIV drugs Tru­va­da and De­scovy for pre-ex­po­sure pro­phy­lax­is (PrEP) in­fringes on gov­ern­ment-owned patents.

While Tru­va­da and De­scovy were ini­tial­ly ap­proved for the treat­ment of HIV back in 2004 and 2016, re­spec­tive­ly, they were lat­er ap­proved in the pre­ven­tive set­ting — Tru­va­da in 2012 and De­scovy in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER